Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Open access

Published version of a preprint

Abstract

Immune checkpoint blockade represents a major breakthrough in cancer therapy; however, responses are not universal. Genomic and immune features in pretreatment tumor biopsies have been reported to correlate with response in patients with melanoma and other cancers, but robust biomarkers have not been identified. We studied a cohort of patients with metastatic melanoma initially treated with cytotoxic T-lymphocyte–associated antigen-4 (CTLA4) blockade (n = 53) followed by programmed death-1 (PD-1) blockade at progression (n = 46), and analyzed immune signatures in longitudinal tissue samples collected at multiple time points during therapy. In this study, we demonstrate that adaptive immune signatures in tumor biopsy samples obtained early during the course of treatment are highly predictive of response to immune checkpoint blockade and also demonstrate differential effects on the tumor microenvironment induced by CTLA4 and PD-1 blockade. Importantly, potential mechanisms of therapeutic resistance to immune checkpoint blockade were also identified. Significance: These studies demonstrate that adaptive immune signatures in early on-treatment tumor biopsies are predictive of response to checkpoint blockade and yield insight into mechanisms of therapeutic resistance. These concepts have far-reaching implications in this age of precision medicine and should be explored in immune checkpoint blockade treatment across cancer types. Cancer Discov; 6(8); 827–37. ©2016 AACR. See related commentary by Teng et al., p. 818. This article is highlighted in the In This Issue feature, p. 803

Overview

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-15-1545

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 45 references

Cited by

See all 1,000

Metadata

Authors
Chen, P.-L., Roh, W., Reuben, A., Cooper, Z. A., Spencer, C. N., Prieto, P. A., Miller, J. P., Bassett, R. L., Gopalakrishnan, V., Wani, K., De Macedo, M. P., Austin-Breneman, J. L., Jiang, H., Chang, Q., Reddy, S. M., Chen, W.-S., Tetzlaff, M. T., Broaddus, R. J., Davies, M. A., Gershenwald, J. E., Haydu, L., Lazar, A. J., Patel, S. P., Hwu, P., Hwu, W.-J., Diab, A., Glitza, I. C., Woodman, S. E., Vence, L. M., Wistuba, I. I., Amaria, R. N., Kwong, L. N., Prieto, V., Davis, R. E., Ma, W., Overwijk, W. W., Sharpe, A. H., Hu, J., Futreal, P. A., Blando, J., Sharma, P., Allison, J. P., Chin, L., & Wargo, J. A.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • 5Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • 2Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Harvard University (US)
Corresponding author
Wargo, Jennifer A.
Venue
Cancer Discovery
Published
2016-08-01
Volume
6
Issue
8
Pages
827-837
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2435243879
Cited by
988
References
45
Citations by year
2026: 34 · 2025: 56 · 2024: 82 · 2023: 89 · 2022: 99 · 2021: 182 · 2020: 140 · 2019: 100 · 2018: 87 · 2017: 99 · 2016: 14
FWCI
53.86
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (U54CA163125, T32CA009666, T32CA163185, K08CA160692, T32CA009599, P30CA016672)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
immune checkpoint blockade, CTLA-4 blockade, anti-PD-1 therapy, metastatic melanoma, immune signatures, predictive biomarkers, treatment response, treatment resistance, tumor microenvironment, adaptive immunity
MeSH terms
Antibodies, Monoclonal, Antineoplastic Agents, Biopsy, Humans, Immunohistochemistry, Melanoma, Neoplasms, Prognosis, Biomarkers, Cluster Analysis, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, Drug Resistance, Neoplasm, Gene Expression Profiling, Immunomodulation, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. https://app.cochat.ai/papers/10.1158/2159-8290.cd-15-1545
The paper
Chen, P.-L., Roh, W., Reuben, A., Cooper, Z. A., Spencer, C. N., Prieto, P. A., Miller, J. P., Bassett, R. L., Gopalakrishnan, V., Wani, K., De Macedo, M. P., Austin-Breneman, J. L., Jiang, H., Chang, Q., Reddy, S. M., Chen, W.-S., Tetzlaff, M. T., Broaddus, R. J., Davies, M. A., . . . Wargo, J. A. (2016). Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-15-1545

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.